C2N Diagnostics Unveils Breakthrough Alzheimer’s Blood Test
C2N Diagnostics announced the planned launch of its new diagnostic blood test, PrecivityAD2, which uses mass spectrometry and a statistical algorithm to detect the two key drivers behind Alzheimer’s disease — tau and amyloid beta proteins.
The test calculates an amyloid probability score to detect whether a patient is positive or negative for brain amyloid plaques, which can cause this form of dementia. The test uses a blood sample instead of PET scans and spinal taps.
The company said clinical studies show that the test is comparable to the current standards at a lower cost and with less discomfort to the patient.
PrecivityAD2 is a new version of the firm’s PrecivityAD, a test that calculates an amyloid beta ratio but does not detect tau.
C2N Diagnostics intends to launch the new test in the first quarter of 2023.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May